Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

FCFangping ChenXLXin Li

Discussion

Loading...

Member takes

Overview

Prospective clinical evaluation revealed high efficacy and safety of CAR-T therapy in extramedullary relapsed B-ALL patients after allo-HSCT, suggesting its potential as a treatment option.

Key Points

  • Six of seven patients achieved complete remission following allogeneic CD19 CAR-T therapy, highlighting its effectiveness.
  • One patient experienced grade 3 cytokine release syndrome, while the remaining patients tolerated the treatment well.
  • This clinical analysis evaluated therapy outcomes in high-risk B-cell acute lymphoblastic leukemia patients post-transplantation.
  • Allogeneic CAR-T therapy may improve treatment strategies for patients facing extramedullary relapse in B-ALL.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de50https://doi.org/10.1182/blood-2025-1547
View Full Paper
Ask AI
Bookmark
Share